1. Home
  2. LWLG vs ANNX Comparison

LWLG vs ANNX Comparison

Compare LWLG & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightwave Logic Inc.

LWLG

Lightwave Logic Inc.

HOLD

Current Price

$4.14

Market Cap

625.9M

Sector

Industrials

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$3.70

Market Cap

726.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LWLG
ANNX
Founded
1991
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
625.9M
726.1M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
LWLG
ANNX
Price
$4.14
$3.70
Analyst Decision
Buy
Buy
Analyst Count
2
10
Target Price
$9.00
★ $17.00
AVG Volume (30 Days)
3.4M
★ 3.4M
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.79
N/A
EPS
★ N/A
N/A
Revenue
★ $236,855.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$998.56
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 147.74
N/A
52 Week Low
$2.84
$2.54
52 Week High
$18.71
$7.18

Technical Indicators

Market Signals
Indicator
LWLG
ANNX
Relative Strength Index (RSI) 39.41 41.32
Support Level $3.80 $3.36
Resistance Level $5.73 $4.37
Average True Range (ATR) 0.35 0.24
MACD -0.02 0.02
Stochastic Oscillator 22.19 40.85

Price Performance

Historical Comparison
LWLG
ANNX

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: